Safety and Efficacy of NeuroTechR3 System for Upper Extremity Recovery After Stroke (R3)

August 12, 2026 updated by: mark.bowden, Brooks Rehabilitation
This research aims to understand the feasibility and effectiveness of using the NeuroTechR3 System to improve upper extremity function after stroke.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Florida
      • Jacksonville, Florida, United States, 32258
        • Recruiting
        • Brooks Rehabilitation Hospital - Bartram Campus
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age ≥18 years at the time of enrollment
  • Diagnosed with stroke
  • No other peripheral or central neurological condition limiting target upper extremity function (previous stroke is ok)
  • Indicated for upper extremity training procedures by participant's treating physician, occupational therapist, or physical therapist
  • Capable of providing informed consent
  • Participant demonstrates active extension of wrist and activation of at least two other digits plus thumb activation

Exclusion Criteria:

  • In the opinion of the investigators, the study is not safe or appropriate for the participant, and/or the participant is unlikely to return for the follow-up visits per the protocol to return the device at 4 weeks post discharge
  • Visual impairment that would severely limit ability to see a computer screen for participation in sessions, including severe spatial neglect making the person unable to interact with an entire computer screen
  • Inability to follow a 3-step motor command
  • Severe upper extremity tone that will limit participation in study
  • No internet access at home
  • Severe receptive aphasia
  • Severe arthritis that limits hand and arm movements
  • Not independent in functional activities/mobility prior to stroke

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: NeuroTechR3 System
Participants will be engaging in six weeks of intervention sessions using the NeuroTechR3 System while in the Brooks Rehabilitation Hospital under the direct supervision of a study staff member. Participants will then take the NeuroTechR3 System and a laptop home to complete intervention sessions in their home after discharge without the supervision of study staff. Each session is 30 minutes and 3 times a week.
Device: NeuroTechR3 Computer Rehabilitation System
Participants will complete three sessions a week, each lasting for 30 minutes. The sessions consist of upper extremity rehabilitation games on the computer.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Upper Extremity Strength and Function
Time Frame: Pre-intervention, mid-intervention within 3 days of discharging from the inpatient rehabilitation facility, and post-intervention at 6 weeks.
The Fugle-Meyer test is a simple, standardized test used to assess a person's exercise capacity and functional mobility. An increase in score reflects an improvement in mobility and upper extremity function.
Pre-intervention, mid-intervention within 3 days of discharging from the inpatient rehabilitation facility, and post-intervention at 6 weeks.
Questionnaires
Time Frame: Mid-intervention within 3 days of discharging from the inpatient rehabilitation facility and post-intervention at 6 weeks.
The System Usability Scale measures the perceived usability, ease of use, and learnability of the system. An increase in score indicates better usability.
Mid-intervention within 3 days of discharging from the inpatient rehabilitation facility and post-intervention at 6 weeks.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Care Transition
Time Frame: Pre-intervention, mid-intervention within 3 days of discharging from the inpatient rehabilitation facility, and post-intervention at 6 weeks.
The NeuroTechR3 System evaluates range of motion, speed, and accuracy for the hand and arm. An increase in kinematic data indicates improved functioning.
Pre-intervention, mid-intervention within 3 days of discharging from the inpatient rehabilitation facility, and post-intervention at 6 weeks.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Brooks Rehabilitation

Collaborators

NeuroTechR3

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 21, 2025

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

August 12, 2026

First Submitted That Met QC Criteria

August 12, 2026

First Posted (Actual)

August 17, 2026

Study Record Updates

Last Update Posted (Actual)

August 17, 2026

Last Update Submitted That Met QC Criteria

August 12, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 00090019

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe